Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection.
10.3350/cmh.2014.20.4.368
- Author:
Yoo Kyung CHO
1
;
Young Nam KIM
;
Byung Cheol SONG
Author Information
1. Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea. drsong@jejunu.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Acute hepatitis C;
Spontaneous viral clearance;
Interferon;
HCV RNA
- MeSH:
Acute Disease;
Adolescent;
Adult;
Aged;
Antiviral Agents/therapeutic use;
Child;
Child, Preschool;
Female;
Genotype;
Hepacivirus/*genetics;
Hepatitis C/*diagnosis/drug therapy;
Humans;
Male;
Middle Aged;
RNA, Viral/blood;
Recurrence;
*Remission, Spontaneous;
Young Adult
- From:Clinical and Molecular Hepatology
2014;20(4):368-375
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: This study evaluated the predictors of spontaneous viral clearance (SVC), as defined by two consecutive undetectable hepatitis C virus (HCV) RNA tests performed > or =12 weeks apart, and the outcomes of acute hepatitis C (AHC) demonstrating SVC or treatment-induced viral clearance. METHODS: Thirty-two patients with AHC were followed for 12-16 weeks without administering antiviral therapy. RESULTS: HCV RNA was undetectable at least once in 14 of the 32 patients. SVC occurred in 12 patients (37.5%), among whom relapse occurred in 4. SVC was exhibited in 8 of the 11 patients exhibiting undetectable HCV RNA within 12 weeks. HCV RNA reappeared in three patients (including two patients with SVC) exhibiting undetectable HCV RNA after 12 weeks. SVC was more frequent in patients with low viremia than in those with high viremia (55.6% vs. 14.3%; P=0.02), and in patients with HCV genotype non-1b than in those with HCV genotype 1b (57.1% vs. 22.2%; P=0.04). SVC was more common in patients with a > or =2 log reduction of HCV RNA at 4 weeks than in those with a smaller reduction (90% vs. 9.1%, P<0.001). A sustained viral response was achieved in all patients (n=18) receiving antiviral therapy. CONCLUSIONS: Baseline levels of HCV RNA and genotype non-1b were independent predictors for SVC. A > or =2 log reduction of HCV RNA at 4 weeks was a follow-up predictor for SVC. Undetectable HCV RNA occurring after 12 weeks was not sustained. All patients receiving antiviral therapy achieved a sustained viral response. Antiviral therapy should be initiated in patients with detectable HCV RNA at 12 weeks after the diagnosis.
